Cannabis Campaigners' Guide News Database result:


After you have finished reading this article you can click here to go back.

Portugal: Drugs Conference in Lisbon

Euro Weekly News

Sunday 03 Dec 2006

---
FRANCO Frattini, Vice-President of the European Commission, has called
for “continued, concerted and measurable action” to strengthen Europe’s
response to the problems of illegal drugs. Mr Frattini’s remarks were
made during a one-day briefing in Lisbon on the European Monitors Centre
for Drugs and Drug Addiction (EMCDDA’s) 2006 annual report, ahead of its
official launch in Brussels last week. The visit is the second by
Vice-President Frattini to the EMCDDA in Lisbon, reflecting the urgency
attached to addressing drugs problems in Europe. “Only with up-to-date
and reliable intelligence can we improve our responsiveness to Europe’s
evolving drug problems,” said Frattini. The new EMCDDA annual report was
released on November 23 at the European Parliament. As European
Commissioner for Justice, Freedom and Security, Mr Frattini is
responsible for the EU drugs portfolio, overseeing implementation of the
2005–2012 EU drugs strategy and its current Action Plan (2005–2008).
Meeting with EMCDDA Director Wolfgang Götz and staff members, Mr
Frattini underlined the value of the EMCDDA as provider of the annual
snapshot of the European drugs situation. Around 80 actions are planned
to be implemented in line with the EU Drugs Action Plan 2005–2008. The
Commission, which is responsible for monitoring and evaluation of the
plan, presents annual progress reviews on the campaign’s implementation,
in order to identify gaps and possible new challenges. The EMCDDA makes
an important contribution to this, providing data collected and analysed
from the Member States. Commenting after the briefing, Frattini said:
“The new EMCDDA annual report gives us cause for both optimism and
concern. First of all, considerable progress has been made in exchanging
information on drug problems —not only internally among Member States,
acceding and candidate countries, but also with countries and
organisations outside the EU. Also encouraging are new targeted
legislative actions aimed at breaking key links in the drug supply
chain, including two regulations controlling precursor chemicals and the
establishment of EU-wide minimum penalties against drug traffickers. We
have also built what is effectively an ‘early-warning system’ for
emerging threats, enabling Europe to assess with confidence the risks of
new psychoactive substances that are currently not controlled under
existing legislation. But we also face worrying findings. Record levels
of heroin seizures in Europe must be seen in the context of increasing
production in Afghanistan, and we cannot be complacent about the
possible impact of the increasing availability of this heroin on the
streets of Europe. Similarly, cocaine seizures continue to grow and
there is evidence that cocaine cartels are increasingly targeting
European markets.”

The EMCDDA 2006 annual report states that opportunities for drug
treatment across Europe are being widened, diverting drug-dependent
users away from the criminal justice system and towards treatment and
rehabilitation.

At the same time, there is a shift in enforcement efforts towards
increased penalties for supply and trafficking and a reduced emphasis on
custodial sentences for drug possession for personal use. The report
also concludes that cannabis is by far the illegal substance most
commonly used in Europe. Recent population surveys indicate that between
two to 31 per cent of adults (aged 15 to 64 years) have tried the
substance at least once, depending on the country. A rough European
estimate would be around 20 per cent of adults having ever tried
cannabis, representing 65 million European adults. As with other illegal
drugs, rates of cannabis use are notably higher among males than among
females. Traditionally, population surveys showed that after cannabis,
amphetamines were the illegal substance most commonly used, albeit their
overall prevalence is clearly lower than that of cannabis. But this
pattern seems to be now changing with Ecstasy taking second place after
cannabis. According to recent surveys, among all adults (15 to 64
years), lifetime experience with amphetamine ranged from 0.1 per cent to
5.9 per cent in EU Member States, except in the United Kingdom, where it
was 11.2 per cent. Among young adults (15 to 34 years), lifetime
experience with amphetamines ranges from 0.1 per cent to 9.6 per cent,
with the United Kingdom reporting 16.5 per cent (although in this
country recent or current use figures are more in line with other
European countries).

Ecstasy has been tried by 2.6 percent on average in the European Union.
National population surveys show that between 0.4 percent and 6 percent
of the general adult population reports have tried cocaine at least
once, with the highest levels found in Spain, Italy and United Kingdom,
representing about 10 million Europeans.

As with other drugs, younger adults present higher rates of cocaine use.
There has been warning about increases in cocaine use in Europe,
prompted by local reports, focused studies conducted in dance settings
and increases in seizures indicators. Clear increases were documented in
the United Kingdom and Spain during the 1990s and early 2000s.
http://www.euroweeklynews.com/ewn/news.php?ref=030812855545310

 

 

 

After you have finished reading this article you can click here to go back.




This page was created by the Cannabis Campaigners' Guide.
Feel free to link to this page!